CD34 and leukemia: Bone marrow ablation was performed in one study in HIV-infected individuals with leukaemia [26], but in that study only a low percentage (<0.2%) of total CD34+ HSC received the gene construct, which resulted in persistent albeit low-level gene marking in peripheral blood (<0.2%) at 18 months post-infusion.